Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany

A needlestick injury occurred during an animal experiment in the biosafety level 4 laboratory in Hamburg, Germany, in March 2009. The syringe contained Zaire ebolavirus (ZEBOV) mixed with Freund's adjuvant. Neither an approved treatment nor a postexposure prophylaxis (PEP) exists for Ebola hemo...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases Vol. 204 Suppl 3; p. S785
Main Authors: Günther, Stephan, Feldmann, Heinz, Geisbert, Thomas W, Hensley, Lisa E, Rollin, Pierre E, Nichol, Stuart T, Ströher, Ute, Artsob, Harvey, Peters, Clarence J, Ksiazek, Thomas G, Becker, Stephan, ter Meulen, Jan, Olschläger, Stephan, Schmidt-Chanasit, Jonas, Sudeck, Hinrich, Burchard, Gerd D, Schmiedel, Stefan
Format: Journal Article
Language:English
Published: United States 01.11.2011
Subjects:
Animals
Containment of Biohazards
Ebola Vaccines - administration & dosage
Ebola Vaccines - standards
Ebolavirus
Germany
Hemorrhagic Fever, Ebola - prevention & control
Humans
Laboratory Infection - prevention & control
Mice
Needlestick Injuries - virology
Occupational Exposure
Post-Exposure Prophylaxis - methods
Research Personnel
RNA, Viral - blood
Vaccines, Attenuated
Vaccines, DNA - immunology
Vesiculovirus - genetics
Viremia
Germany
ISSN:1537-6613, 1537-6613
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A needlestick injury occurred during an animal experiment in the biosafety level 4 laboratory in Hamburg, Germany, in March 2009. The syringe contained Zaire ebolavirus (ZEBOV) mixed with Freund's adjuvant. Neither an approved treatment nor a postexposure prophylaxis (PEP) exists for Ebola hemorrhagic fever. Following a risk-benefit assessment, it was recommended the exposed person take an experimental vaccine that had shown PEP efficacy in ZEBOV-infected nonhuman primates (NHPs) [12]. The vaccine, which had not been used previously in humans, was a live-attenuated recombinant vesicular stomatitis virus (recVSV) expressing the glycoprotein of ZEBOV. A single dose of 5 × 10(7) plaque-forming units was injected 48 hours after the accident. The vaccinee developed fever 12 hours later and recVSV viremia was detectable by polymerase chain reaction (PCR) for 2 days. Otherwise, the person remained healthy, and ZEBOV RNA, except for the glycoprotein gene expressed in the vaccine, was never detected in serum and peripheral blood mononuclear cells during the 3-week observation period.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:1537-6613
1537-6613
DOI:10.1093/infdis/jir298